LG Chem launches filler's clinical trial in China

Revealed premium line clinical trial plan of Yvoire Y-Solution

china's filler market share (Source: 2019 Samsung securities reasearch)

LG Chem is launching a large-scale clinical trial in China with the new product of Yvoire, a hyaluronic acid filler brand.

 

It is an ambition to secure the differentiation and expand the market share by preparing clinical data of Y-Solution, which was introduced as a premium line.

 

LG Chem recently unveiled a new clinical trial plan for Yvoire Y-Solution on clinicaltrials.gov, a clinical trial registration site operated by the National Institutes of Health (NIH).

 

This study is to check the effect and safety of the volume improvement of Y-Solution 720 for 238 subjects.

 

The researchers decided to evaluate the effectiveness by confirming the MFVDS (Mid-Face Volume Deficit Scale) response rate, which is used as a measure of the volume recovery of the central part of the face, at week 26 after the injection of Y-Solution 720.

 

The study begins in earnest from this month and is scheduled to proceed until July 2022.

 

Professor Xiaojun Wang of Peking Union Medical College Hospital was appointed as the Principal Researcher (PI).

 

Yvoire Y-Solution is a premium product among LG Chem's hyaluronic acid filler brand 'Yvoire'.

 

LG Chem introduced Y-Solution series in 2018 to target the premium wrinkle improver market.

 

According to the volume improvement effect, it is composed of three types: 'Y-Solution 360', 'Y-Solution 540', and 'Y-Solution 720'.

 

According to the company, it is expected that the volume improvement effect will be further improved by supplementing the existing product 'Yvoire' with additional viscosity.

 

It is interpreted as the will of LG Chem to actively target the overseas market with filler products.

 

LG Chem started exporting to Russia in 2012 and has exported Yvoire to more than 30 countries including China, France, the UK, Italy and Mexico.

 

China's filler market share (Source: 2019 Samsung securities report)

In the case of the Chinese market, it has secured the initiative by introducing the existing Yvoire products early.

 

According to the '2019 Healthcare Report' published by Samsung Securities, among the 7 companies that occupy the hyaluronic acid filler market in China, LG Chem and Humedix are included in Korean companies.

 

LG Chem's 'Yvoire' market share is about 26%, and Elravie by Humedix is about 13%.

 

It is judged that it is necessary to rapidly increase the penetration rate of the market through the launch of new products as China has rapidly emerged as a base for filler industries worldwide.

 

LG Chem is conducting a clinical trial comparing 'Y-Solution 360' with Allergen’s Juvederm in Germany.

 

An official from LG Chem said, "Yvoire has maintained the best selling fillers in the Chinese market by surpassing Chinese local brands and global brands for 4 consecutive years since 2016." "In the future, we plan to expand the sales of Yvre in the center of Europe and South America as a global brand" added him.